Compare Gilead Sciences, Inc. (GILD) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Snap Inc — how do they compare? Gilead Sciences, Inc. trades at $135.56 (market cap $163.51B), while Snap Inc trades at $4.75 (market cap $8.01B). The key difference: Gilead Sciences, Inc. is far larger — about 20.4× Snap Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Snap Inc pays none. Which is the better fit depends on your goals.
| GILD | SNAP | |
|---|---|---|
Market Cap | $163.51B | $8.01B |
Sector | Health | Media |
52-Week High | $155.80 | $10.35 |
52-Week Low | $108.22 | $3.93 |
Enterprise Value | $178.05B | $9.39B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Snap Inc. (SNAP) trades at $4.73, up 1.39% with a bullish technical signal despite negative profitability. Revenue grew to $5.93B in 2025, with improving net margins from -31.07% in 2022 to -7.77%. Recent earnings beats and cost-cutting efforts contrast with high debt and AR glasses launch concerns. Cash flow trends show operational improvement, though net income remains negative.
Outlook hinges on monetization and cost control amid competitive pressures. Analysts see 22% upside to $5.75 target, but risks include stagnant user growth and regulatory scrutiny. The stock offers speculative growth potential if profitability targets are met, balanced by significant execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
